Agenus names Robin Taylor, Homa Yeganegi, Stephanie Fagan to executive team

Agenus announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company’s next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Taylor, Ph.D., is an accomplished leader with demonstrated success in global commercial development in oncology. His expertise in commercialization strategies, market access, and product launches will accelerate Agenus’ growth and ultimately enable the delivery of the company’s therapies to patients as the company evolves to a multi-product organization. Chief Product Strategy and Global Medical Affairs Officer, Homa Yeganegi, brings expertise in medical affairs and a passion for advancing patient care. Her success in building and leading global medical affairs teams will play a pivotal role in deepening physicians’ understanding of the transformational potential of botensilimab. By fostering strong relationships with the medical community, she will contribute to the development and future commercialization of the company’s immuno-oncology programs.